Immune system secrets may improve breast cancer therapy
NCT ID NCT04614194
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study aims to understand how the immune system reacts to a common breast cancer treatment combination of letrozole and abemaciclib. Researchers will collect tumor and blood samples from 60 postmenopausal women with hormone receptor-positive breast cancer before and after two weeks of treatment. The goal is to see if immune cell changes can predict how well the cancer responds, which could help personalize future therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parkland Hospital
NOT_YET_RECRUITINGDallas, Texas, 75039, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
letrozole and abemaciclib
What this could lead to
If successful, this could reveal how the immune system helps fight breast cancer, potentially guiding better treatment combinations in the future.
What could go wrong
This is a small, early-phase study focused on understanding immune changes, not on proving a new treatment works. Results may not lead to direct patient benefits.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.